Active substances

Dabigatran etexilat›

B01AE07 Blood and blood forming organs | Antithrombotic agents | Antithrombotic agents | Direct thrombin inhibitors

Indicated for: prevention and treatment of thromboembolism

Dabrafenib›

L01EC02 Antineoplastic and immunomodulating agents | Protein kinase inhibitors | B-raf serine-threonine kinase (BRAF) inhibitors

Indicated for: melanoma

Dacarbazine›

L01AX04 Antineoplastic and immunomodulating agents | Alkylating agents | Other alkylating agents

Indicated for: cancer

Daclatasvir›

J05AX14 Antiinfectives for systemic use | Direct acting antivirals | Other antivirals

Indicated for: chronic hepatitis C

Daclizumab›

L04AA08 Antineoplastic and immunomodulating agents | Immunosuppressants | Immunosuppressants | Selective immunosuppressants

Indicated for: multiple sclerosis

Dacomitinib›

L01EB07 Antineoplastic and immunomodulating agents | Protein kinase inhibitors | Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors

Indicated for: cancer

Dactynomicin›

L01DA01 Antineoplastic and immunomodulating agents | Cytotoxic antibiotics and related substances | Actinomycines

Indicated for: cancer

Dalbavancin›

J01XA04 Antiinfectives for systemic use | Other antibacterials | Glycopeptide antibacterials

Indicated for: bacterial infections

Dalteparin›

B01AB04 Blood and blood forming organs | Antithrombotic agents | Antithrombotic agents | Heparin group

Indicated for: prevention and treatment of thromboembolism

Damoctocog alfa pegol›

B02BD02 Blood and blood forming organs | Vitamin k and other hemostatics | Blood coagulation factors

Indicated for: bleeding; coagulation disorders

Dandelion›

A05AXN1 Alimentary tract and metabolism | Bile therapy | Other drugs for bile therapy

Indicated for: mild digestive disorders; support of bile flow; diuresis

Danicopan›

L04AJ09 Antineoplastic and immunomodulating agents | Immunosuppressants | Immunosuppressants | Complement inhibitors

Indicated for: complement-mediated disorders

Dantrolen sodium›

M03CA01 Musculo-skeletal system | Muscle relaxants | Muscle relaxants, directly acting agents | Dantrolene and derivatives

Indicated for: spasticity; muscle spasms

Dapagliflozin›

A10BK01 Alimentary tract and metabolism | Blood glucose lowering drugs, excl. insulins | Sodium-glucose co-transporter 2 (SGLT2) inhibitors

Indicated for: type 2 diabetes; heart failure; chronic kidney disease

Dapagliflozin + metformin›

A10BD15 Alimentary tract and metabolism | Blood glucose lowering drugs, excl. insulins | Combinations of oral blood glucose lowering drugs

Indicated for: type 2 diabetes mellitus

Dapoxetine›

G04BX14 Genito urinary system and sex hormones | Urologicals | Urologicals | Other urologicals

Indicated for: premature ejaculation

Dapsone›

J04BA02 Antiinfectives for systemic use | Drugs for treatment of lepra

Indicated for: bacterial infections

Daptomycin›

J01XX09 Antiinfectives for systemic use | Other antibacterials

Indicated for: bacterial infections

Daratumumab›

L01FC01 Antineoplastic and immunomodulating agents | Monoclonal antibodies and antibody drug conjugates | Cd38 (clusters of differentiation 38) inhibitors

Indicated for: hematologic malignancies

Darbepoetin alfa›

B03XA02 Blood and blood forming organs | Other antianemic preparations

Indicated for: anemia

Darifenacin›

G04BD10 Genito urinary system and sex hormones | Urologicals | Urologicals | Drugs for urinary frequency and incontinence

Indicated for: overactive bladder; urinary incontinence

Darolutamide›

L02BB06 Antineoplastic and immunomodulating agents | Hormone antagonists and related agents | Anti-androgens

Indicated for: prostate cancer

Darunavir›

J05AE10 Antiinfectives for systemic use | Direct acting antivirals | Protease inhibitors

Indicated for: HIV-1 infection

Darunavir + cobicistat›

J05AR14 Antiinfectives for systemic use | Direct acting antivirals | Antivirals for treatment of HIV infections, combinations

Indicated for: HIV-1 infection

Darunavir + cobicistat + emtricitabine + tenofovir alafenamide›

J05AR22 Antiinfectives for systemic use | Direct acting antivirals | Antivirals for treatment of HIV infections, combinations

Indicated for: HIV-1 infection

Darvadstrocel›

L04AX08 Antineoplastic and immunomodulating agents | Immunosuppressants | Immunosuppressants | Other immunosuppressants

Indicated for: complex perianal fistulas in Crohn's disease

Dasabuvir›

J05AP09 Antiinfectives for systemic use | Direct acting antivirals | Antivirals for treatment of HIV infections

Indicated for: chronic hepatitis C

Dasatinib›

L01EA02 Antineoplastic and immunomodulating agents | Protein kinase inhibitors | BCR-ABL tyrosine kinase inhibitors

Indicated for: chronic myeloid leukemia

Datopotamab deruxtecan›

L01FX35 Antineoplastic and immunomodulating agents | Monoclonal antibodies and antibody drug conjugates | Other monoclonal antibodies and antibody drug conjugates

Indicated for: unresectable or metastatic HR-positive, HER2-negative breast cancer after endocrine therapy and at least one chemotherap

Daunorubicin›

L01DB02 Antineoplastic and immunomodulating agents | Cytotoxic antibiotics and related substances | Anthracyclines and related substances

Indicated for: leukemia